Table 1.
(A) Summary of immunohistochemical studies – high CD9 expression associates with good clinical outcome.
| Authors | Tumor Type | Patients | Detection method | Antibody clone | Source | Therapy | Clinical outcome with high CD9 |
|---|---|---|---|---|---|---|---|
| Miyake et al., 1995 (93) | breast ca | 143 | IHC, RT-PCR, western blotting | m31-15 | in-house | S | less aggressive disease |
| Arihiro et al., 1998 (94) | breast ca | 93 | IHC, western blotting | n.s. | Dako | S | good prognosis, low risk of LN metastases |
| Houle et al., 2002 (86) | ovarian ca | 40 | IHC | m31-15 | in-house, Dr. Miyake | S/AC | less aggressive disease |
| Sauer et al., 2003 (75) | cervical ca | 44 | IHC | 72F6 | Novocastra | S | good prognosis |
| Miyamoto et al., 2001 (95) | endometrial ca | 71 | IHC | TP82 | Temecula, CA | S | good prognosis |
| Wang et al., 2007 (27) | prostatic ca | 167 | IHC | 72F6 | Novocastra | S | less aggressive disease |
| Mhawech et al., 2003 (96) | urothelial blader ca | 320 | IHC | n.s. | Novocastra | TURBT | good prognosis |
| Ai et al., 2007 (97) | urothelial blader ca | 52 | IHC | n.s. | Jingmei Biotech | TURBT | good prognosis |
| Buim et al., 2010 (98) | oral squamous ca | 179 | IHC, RT-PCR | n.s. | Neomarkers | S | good prognosis |
| Kusukawa et al., 2001 (99) | oral squamous ca | 78 | IHC, western blotting | clone 007 | in-house | S | good prognosis |
| Uchida et al., 1999 (100) | esophageal squamous ca | 108 | IHC | m31-15 | in-house | S | good prognosis |
| Zou et al., 2012 (101) | ca of gallblader | 108 | IHC | n.s. | Dako | S | good prognosis |
| Khushman et al., 2019 (102) | pancreatic ca | 29 | IHC | n.s. | Abcam | S | less aggressive disease |
| Kim et al., 2016 (103) | colorectal ca | 305 | IHC | EPR2949 | Abcam | S/AC | good prognosis in left-side tumors only |
| Hashida et al. 2003 (104) | colorectal ca | 146 | IHC, RT-PCR | m31-15 | in-house | S | good prognosis |
| Amatya et al., 2013 (105) | mesothelioma | 112 | IHC | 72F6 | Novus Biologicals | S/AC/RT | good prognosis |
| Si et Hersey 1993 (106) | melanoma | 55 | IHC | FMC56 | in-house, Dr. Zola | S | less aggressive disease |
| Woegerbauer et al., 2010 (107) | Merkell cell ca | 25 | IHC, RT-PCR, western blotting | RDI-MCD9 | Fitzgerald | S/AC/RT | good prognosis |
| Kohmo et al., 2010 (85) | small cell lung ca | 24 | IHC, RT-PCR, western blotting, flow cytometry | 72F6 | Novocastra | AC | good prognosis |
| Adachi et al., 1998 (108) | non small lung ca | 172 | IHC, RT-PCR | m31-15 | in house | S | good prognosis |
| Higashiyama et al., 1995 (109) | adenoca of lung | 132 | IHC, RT-PCR | m31-15 | in house | S | good prognosis |
AC, adjuvant chemotherapy; ca, carcinoma; IHC, immunohistochemitry; LN, lymph node; NAC, neoadjuvant chemotherapy; n.s. not specified; RT, radiotherapy; S, surgery; TURBT; transuretral resection of bladder tumor.